Product Code: BT 9503
The single-cell sequencing market is expected to reach USD 3.46 billion in 2030 from USD 1.95 billion in 2025, at a CAGR of 12.2% during the forecast period. The growth of this market can be attributed to ongoing technological advancements in single-cell sequencing technologies, which are becoming more accurate, scalable, and efficient.
Scope of the Report |
Years Considered for the Study | 2024-2030 |
Base Year | 2024 |
Forecast Period | 2025-2030 |
Units Considered | Value (USD billion) |
Segments | Offering, Product Type, Product Workflow, Product End User, Service Type, Service End User, Sequencing Type, Application, and End User |
Regions covered | North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa |
For instance, in July 2025, researchers from the Huazhong University of Science and Technology developed the Toti-N-Seq platform to overcome challenges in sample multiplexing and rare cell detection by using a special glycan-binding protein to label all types of cells and nuclei. At the same time, well-established systems like 10x Genomics' Chromium remain essential for extensive studies due to their reliability, high throughput, and broad adoption.
"By type, the sequencing instruments segment is expected to register the highest growth rate during the forecast period."
By type, the single-cell sequencing products market is segmented into consumables, instruments, and software. The instruments segment is further segmented into pre-sequencing and sequencing instruments. The sequencing instruments segment registered the highest CAGR during the forecast period. This growth is primarily driven by the emergence of new sequencing technology providers, such as Pacific Biosciences (PacBio), Oxford Nanopore Technologies, Element Biosciences, and Ultima Genomics, that have introduced platforms compatible with various single-cell sequencing workflows. Additionally, sequencing instruments remain the core technological driver of single-cell sequencing, performing the essential function of decoding nucleic acids at single-cell resolution. As applications of single-cell sequencing expand into areas like oncology, immunology, neuroscience, and microbiome studies, there is a corresponding rise in demand for sequencing instruments capable of handling increasingly complex, large-scale datasets.
"By service type, the sequencing services segment accounted for the largest share of the market in 2024."
Based on service type, the single-cell sequencing market is pre-sequencing services, sequencing services, and data analysis & bioinformatic services. In 2024, the sequencing services segment held the largest share of the single-cell sequencing market by service type. The large share of this service segment can be attributed to the high cost and operational complexity of sequencing instruments. The growing demand for clinical-grade sequencing, higher throughput, and standardized data output has also driven the expansion of professional sequencing services, reinforcing their leading position in the market. Moreover, with the rising adoption of single-cell technologies in translational research and clinical studies, sequencing services offer a scalable and compliant solution for handling large sample volumes.
"The Asia Pacific region is expected to grow at the highest CAGR in the single-cell sequencing market during the forecast period."
The market is segmented by region into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is projected to register the highest CAGR in the single-cell sequencing market during the forecast period. The key factors driving the market growth include expanding biomedical research infrastructure, rising government funding, and increasing adoption of single-cell technologies in clinical and academic settings. Countries like China, Japan, and South Korea actively invest in genomics through national initiatives and grants. At the same time, companies such as Singleron Biotechnologies and Macrogen make the technology more accessible across research and diagnostic markets. The region's large and genetically diverse populations offer vast opportunities for disease-specific single-cell studies, particularly in oncology and infectious diseases. Additionally, lower operational costs and growing outsourcing of sequencing services to Asia-based CROs further accelerate regional growth, making the Asia Pacific a key engine of expansion for the global single-cell sequencing market.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24%
- By Designation: (Managers)- 45%, (CXOs, Directors)- 30%, and (Executives)- 25%
- By Region: North America- 40%, Europe- 25%, Asia Pacific- 20%, and the Rest of the World- 15%
10x Genomics (US), Illumina Inc. (US), BD (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Bio-Techne (US), and PacBio (US) are some of the key players in the single-cell sequencing market.
The study includes an in-depth competitive analysis of these key players in the single-cell sequencing market, with their company profiles, recent developments, and key market strategies.
Research Coverage:
This research report categorizes the single cell sequencing market by offering (products, services), by product type (consumables [pre-sequencing, sequencing], instruments [pre-sequencing instruments {microfluidics, PCR, LCM, FACs, others}, sequencing platforms], software), by product workflow (pre-sequencing, sequencing, software), by product end user (hospitals & diagnostic laboratories, academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations), by service type (pre-sequencing services [sample preparation, library preparation], sequencing services, bioinformatics services), by service end users (hospitals & diagnostic laboratories, academic & research institutes, pharmaceutical & biotechnology companies), by sequencing type (single cell transciptome sequencing, single cell genome sequencing, single cell ATAC sequencing, others), by application (research application [basic & translation research {cancer research, stem cell & developmental biology, neurology & brain research, microbiology & infectious disease, organ development & regenerative medicine}, drug discovery & development], diagnostic & clinical application), by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The report provides in-depth information on significant factors influencing the growth of the single-cell sequencing market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches and acquisitions within the single-cell sequencing market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall single-cell sequencing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (Advancements in Single-Cell sequencing technologies, Growing Demand for Personalized Medicine and Biomarker Discovery, Integration of AI and ML in data analysis, Advantages over bulk sequencing), restraints (High cost of single cell sequencing and analysis products), opportunities (Development of Sequencing by Expansion (SBX) technology, Growing clinical applications), and challenges (Data Complexities and Analysis Bottleneck) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products/services of the single-cell sequencing market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the single-cell sequencing market
- Competitive Assessment: In-depth assessment of market share, growth strategies and service offerings of leading players like 10x Genomics (US), Illumina Inc. (US), BD (US), Danaher (US), Thermo Fisher Scientific Inc. (US), Qiagen (Netherlands), and Pacbio (US) among others, in the single-cell sequencing market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
- 1.3.1 MARKETS & REGIONS COVERED
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 MARKET STAKEHOLDERS
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.2 PRIMARY DATA
- 2.2 MARKET ESTIMATION METHODOLOGY
- 2.2.1 MARKET SIZE ESTIMATION
- 2.2.2 SEGMENTAL MARKET ASSESSMENT
- 2.3 MARKET GROWTH RATE PROJECTIONS
- 2.4 DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
- 3.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
- 3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS
- 3.3 DISRUPTIVE TRENDS SHAPING MARKET
4 PREMIUM INSIGHTS
- 4.1 SINGLE-CELL SEQUENCING MARKET SNAPSHOT
- 4.2 NORTH AMERICA: SINGLE-CELL SEQUENCING MARKET, BY OFFERING & COUNTRY (2024)
- 4.3 SINGLE-CELL SEQUENCING MARKET FOR BASIC & TRANSLATION RESEARCH APPLICATIONS, BY TYPE (2024)
- 4.4 SINGLE-CELL SEQUENCING PRODUCTS MARKET, BY END USER (2024)
- 4.5 SINGLE-CELL SEQUENCING SERVICES MARKET, BY END USER (2024)
- 4.6 SINGLE-CELL SEQUENCING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Advancements in single-cell sequencing technologies
- 5.2.1.2 Growing focus on precision medicine and biomarker discovery
- 5.2.1.3 Integration of AI & ML in data analysis
- 5.2.1.4 Advantages over conventional bulk sequencing
- 5.2.2 RESTRAINTS
- 5.2.2.1 High cost of single-cell sequencing products & services
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Emergence of SBX technology
- 5.2.3.2 Integration of multi-omics technologies
- 5.2.3.3 Growth potential of emerging economies
- 5.2.4 CHALLENGES
- 5.2.4.1 Complexities associated with high-dimensional single-cell data
- 5.2.4.2 Biological variability and cell heterogeneity
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 ECOSYSTEM ANALYSIS
- 5.5.1 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFT IN SINGLE-CELL SEQUENCING MARKET
- 5.6 TECHNOLOGY ANALYSIS
- 5.6.1 KEY TECHNOLOGIES
- 5.6.1.1 Microfluidics partitioning
- 5.6.1.2 NGS
- 5.6.1.3 PCR
- 5.6.1.4 Flow cytometry
- 5.6.2 COMPLEMENTARY TECHNOLOGIES
- 5.6.2.1 Magnetic-activated Cell Sorting (MACS)
- 5.6.2.2 Tissue dissociation systems
- 5.6.2.3 Combinatorial indexing
- 5.6.3 ADJACENT TECHNOLOGIES
- 5.6.3.1 Bulk RNA-seq
- 5.6.3.2 In situ hybridization (ISH)
- 5.7 PATENT ANALYSIS
- 5.7.1 PATENT METHODOLOGY
- 5.7.2 PATENTS APPLIED & GRANTED, 2014-2024
- 5.8 TRADE ANALYSIS
- 5.8.1 IMPORT DATA (HS CODE 9027)
- 5.8.2 EXPORT DATA (HS CODE 9027)
- 5.9 PORTER'S FIVE FORCES ANALYSIS
- 5.9.1 THREAT OF NEW ENTRANTS
- 5.9.2 THREAT OF SUBSTITUTES
- 5.9.3 BARGAINING POWER OF SUPPLIERS
- 5.9.4 BARGAINING POWER OF BUYERS
- 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.10 TARIFF & REGULATORY LANDSCAPE
- 5.10.1 TARIFF DATA (HS CODE 9027)
- 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.10.3 REGULATORY FRAMEWORK
- 5.11 PRICING ANALYSIS
- 5.11.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022 -2024
- 5.11.2 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2024
- 5.12 KEY CONFERENCES & EVENTS, 2025-2026
- 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.13.2 ROLE OF STAKEHOLDERS IN BUYING PROCESS
- 5.13.3 BUYING CRITERIA
- 5.14 CUSTOMER LANDSCAPE
- 5.14.1 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
- 5.14.2 UNMET NEEDS & WHITE SPACES
- 5.15 INVESTMENT & FUNDING ACTIVITIES
- 5.16 IMPACT OF AI/GENERATIVE AI ON SINGLE-CELL SEQUENCING MARKET
- 5.16.1 AI-USE CASES
- 5.16.2 KEY COMPANIES IMPLEMENTING AI
- 5.16.3 FUTURE OF AI IN SINGLE-CELL SEQUENCING
- 5.17 TRUMP TARIFF IMPACT ON SINGLE-CELL SEQUENCING MARKET
- 5.17.1 INTRODUCTION
- 5.17.2 KEY TARIFF RATES
- 5.17.3 PRICE IMPACT ANALYSIS
- 5.17.4 KEY IMPACT ON VARIOUS REGIONS
- 5.17.4.1 US
- 5.17.4.2 Europe
- 5.17.4.3 Asia Pacific
- 5.17.4.4 Rest of the World
- 5.17.5 END-USE INDUSTRY IMPACT
- 5.17.5.1 Pharmaceutical & biotech companies
- 5.17.5.2 CROs
- 5.17.5.3 Academic & research institutes
- 5.17.5.4 Hospitals & clinical laboratories
6 SINGLE-CELL SEQUENCING MARKET, BY OFFERING
- 6.1 INTRODUCTION
- 6.2 PRODUCTS
- 6.2.1 RECURRING DEMAND FOR CONSUMABLES TO DRIVE MARKET
- 6.3 SERVICES
- 6.3.1 HIGH RELIANCE ON SERVICE PROVIDERS FOR SEQUENCING ACTIVITIES TO PROPEL MARKET
7 SINGLE-CELL SEQUENCING PRODUCT MARKET, BY TYPE
- 7.1 INTRODUCTION
- 7.2 CONSUMABLES
- 7.2.1 PRE-SEQUENCING REAGENTS & KITS
- 7.2.1.1 Ongoing product launches & upgrades to fuel uptake
- 7.2.2 SEQUENCING REAGENTS & KITS
- 7.2.2.1 Ability to provide high-throughput and high-fidelity nucleotide reading to boost demand
- 7.3 INSTRUMENTS
- 7.3.1 PRE-SEQUENCING INSTRUMENTS
- 7.3.1.1 Microfluidic instruments
- 7.3.1.1.1 Increasing demand for reproducible & low-input single-cell workflows to fuel uptake
- 7.3.1.2 Cell sorters
- 7.3.1.2.1 Provision of high-precision isolation of viable cells to boost demand
- 7.3.1.3 PCR instruments
- 7.3.1.3.1 High sensitivity & reproducibility features to fuel uptake
- 7.3.1.4 LCM instruments
- 7.3.1.4.1 Increasing use across applications requiring spatial resolution to support demand
- 7.3.1.5 Other pre-sequencing instruments
- 7.3.2 SEQUENCING PLATFORMS
- 7.3.2.1 Rising adoption across research applications to drive market
- 7.4 SOFTWARE
- 7.4.1 SOFTWARE TOOLS
- 7.4.1.1 Rising demand for accurate & scalable processing of sequencing data to support market growth
- 7.4.2 DATA STORAGE & MANAGEMENT SOFTWARE
- 7.4.2.1 Secure handling, archival, and retrieval of large volumes of data to support market growth
8 SINGLE-CELL SEQUENCING PRODUCT MARKET, BY WORKFLOW
- 8.1 INTRODUCTION
- 8.2 PRE-SEQUENCING WORKFLOW
- 8.2.1 ABILITY TO ENABLE HIGH-THROUGHPUT WORKFLOW IN CLINICAL & RESEARCH SETTINGS TO DRIVE MARKET
- 8.3 SEQUENCING WORKFLOW
- 8.3.1 DEMAND FOR MULTI-OMIC SEQUENCING PLATFORMS IN TRANSLATIONAL RESEARCH & ONCOLOGY TO PROPEL MARKET
- 8.4 DATA ANALYSIS & INTERPRETATION WORKFLOW
- 8.4.1 COMPLEXITY OF SINGLE-CELL DATASETS TO FUEL MARKET
9 SINGLE-CELL SEQUENCING PRODUCT MARKET, BY END USER
- 9.1 INTRODUCTION
- 9.2 ACADEMIC & RESEARCH INSTITUTES
- 9.2.1 RISING FOCUS ON LIFE SCIENCES RESEARCH SUPPORTED BY FAVORABLE GRANTS & FUNDS TO DRIVE MARKET
- 9.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 9.3.1 INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET
- 9.4 HOSPITALS & CLINICAL LABORATORIES
- 9.4.1 RISING INTEGRATION OF ADVANCED SEQUENCING TECHNOLOGIES INTO CLINICAL WORKFLOWS TO BOOST DEMAND
- 9.5 CONTRACT RESEARCH ORGANIZATIONS (CROS)
- 9.5.1 INCREASING RELIANCE ON OUTSOURCING R&D ACTIVITIES TO SUPPORT MARKET GROWTH
10 SINGLE-CELL SEQUENCING SERVICES MARKET, BY TYPE
- 10.1 INTRODUCTION
- 10.2 PRE-SEQUENCING SERVICES
- 10.2.1 SAMPLE PREPARATION, SINGLE-CELL ISOLATION, AND ENRICHMENT SERVICES
- 10.2.1.1 Rising demand for high-resolution cell profiling services to fuel market
- 10.2.2 LIBRARY PREPARATION SERVICES
- 10.2.2.1 Adoption of single-cell applications to fuel market
- 10.3 SEQUENCING SERVICES
- 10.3.1 INCREASING DEMAND FOR SCALABLE & APPLICATION-SPECIFIC SEQUENCING OUTPUTS TO DRIVE MARKET
- 10.4 DATA ANALYSIS & BIOINFORMATICS SERVICES
- 10.4.1 INCREASING FOCUS ON CREATION OF END-TO-END ANALYSIS PIPELINES TO SUPPORT MARKET GROWTH
11 SINGLE-CELL SEQUENCING SERVICES MARKET, BY END USER
- 11.1 INTRODUCTION
- 11.2 ACADEMIC & RESEARCH INSTITUTES
- 11.2.1 EXECUTION OF COMPLEX & LARGE-SCALE CELLULAR STUDIES TO DRIVE MARKET
- 11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 11.3.1 INTEGRATION OF HIGH-THROUGHPUT SINGLE-CELL PLATFORMS IN DRUG DISCOVERY ACTIVITIES TO PROPEL MARKET
- 11.4 HOSPITALS & CLINICAL LABORATORIES
- 11.4.1 INCREASING USE ACROSS ONCOLOGY DIAGNOSTICS TO SUPPORT MARKET GROWTH
12 SINGLE-CELL SEQUENCING MARKET, BY SEQUENCING TYPE
- 12.1 INTRODUCTION
- 12.2 SINGLE-CELL TRANSCRIPTOME SEQUENCING (SCRNA-SEQ)
- 12.2.1 WIDE APPLICATIONS FOR GENE EXPRESSION STUDIES TO DRIVE MARKET
- 12.3 SINGLE-CELL GENOME SEQUENCING (SCDNA-SEQ)
- 12.3.1 ANALYSIS OF GENOMIC VARIATIONS WITH COMPLEX ADVANCEMENTS TO FUEL MARKET
- 12.4 SINGLE-CELL ATAC SEQUENCING (SCATAC-SEQ)
- 12.4.1 IDENTIFICATION OF OPEN DNA REGIONS TO SUPPORT MARKET GROWTH
- 12.5 OTHER SINGLE-CELL SEQUENCING TYPES
13 SINGLE-CELL SEQUENCING MARKET, BY APPLICATION
- 13.1 INTRODUCTION
- 13.2 RESEARCH APPLICATIONS
- 13.2.1 BASIC & TRANSLATION RESEARCH
- 13.2.1.1 Cancer research
- 13.2.1.1.1 Growing demand for oncology therapeutics to drive market
- 13.2.1.2 Stem cell & developmental biology
- 13.2.1.2.1 Mapping stem cell heterogeneity and lineage dynamics with high precision to boost demand
- 13.2.1.3 Neurology & brain research
- 13.2.1.3.1 Growing focus on psychiatric & neurodevelopmental disorder research to fuel market
- 13.2.1.4 Microbiology & infectious diseases
- 13.2.1.4.1 Precise profiling of immune responses & pathogen behavior to boost demand
- 13.2.1.5 Organ development & regenerative medicine
- 13.2.1.5.1 Growing focus on precision medicine to fuel uptake
- 13.2.2 DRUG DISCOVERY & DEVELOPMENT
- 13.2.2.1 Improved target validation and patient stratification using single-cell data to drive market
- 13.3 DIAGNOSTIC & CLINICAL APPLICATIONS
- 13.3.1 RISING UPTAKE IN MOLECULAR DIAGNOSTICS & PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH
14 SINGLE-CELL SEQUENCING MARKET, BY REGION
- 14.1 INTRODUCTION
- 14.2 NORTH AMERICA
- 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 14.2.2 US
- 14.2.2.1 Increasing R&D investments & funding to drive market
- 14.2.3 CANADA
- 14.2.3.1 High prevalence of hemophilia to propel market
- 14.3 EUROPE
- 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 14.3.2 GERMANY
- 14.3.2.1 Increasing awareness of advanced cell therapies to drive market
- 14.3.3 UK
- 14.3.3.1 Rising adoption of single-cell analysis products to boost demand
- 14.3.4 FRANCE
- 14.3.4.1 Favorable government funding investments for genomics to fuel market
- 14.3.5 ITALY
- 14.3.5.1 Growing focus on cell biology research to fuel uptake
- 14.3.6 SPAIN
- 14.3.6.1 Increasing number of biotechnology companies to drive market
- 14.3.7 REST OF EUROPE
- 14.4 ASIA PACIFIC
- 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 14.4.2 CHINA
- 14.4.2.1 Increasing incidence of infectious diseases to drive market
- 14.4.3 JAPAN
- 14.4.3.1 Growing demand for personalized medicine to drive market
- 14.4.4 INDIA
- 14.4.4.1 Expansion of activities in cell biology and biotech sectors to drive market
- 14.4.5 SOUTH KOREA
- 14.4.5.1 Increasing number of strategic alliances to boost market
- 14.4.6 AUSTRALIA
- 14.4.6.1 Rising establishment of life science companies to boost demand
- 14.4.7 REST OF ASIA PACIFIC
- 14.5 LATIN AMERICA
- 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 14.5.2 BRAZIL
- 14.5.2.1 Focus on advancements in manufacturing infrastructure for biopharmaceuticals to propel market
- 14.5.3 MEXICO
- 14.5.3.1 Favorable government support for advanced sequencing technologies to drive market
- 14.5.4 REST OF LATIN AMERICA
- 14.6 MIDDLE EAST
- 14.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST
- 14.6.2 GCC COUNTRIES
- 14.6.2.1 Kingdom of Saudi Arabia (KSA)
- 14.6.2.1.1 Increasing healthcare expenditure to drive market
- 14.6.2.2 United Arab Emirates
- 14.6.2.2.1 Improvements in medical sector to fuel uptake
- 14.6.2.3 Other GCC Countries
- 14.6.3 REST OF MIDDLE EAST
- 14.7 AFRICA
- 14.7.1 RISING FOCUS ON DRUG DISCOVERY & DEVELOPMENT TO SUPPORT MARKET GROWTH
- 14.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
15 COMPETITIVE LANDSCAPE
- 15.1 OVERVIEW
- 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2025
- 15.3 REVENUE ANALYSIS, 2022-2024
- 15.4 MARKET SHARE ANALYSIS, 2024
- 15.5 COMPANY EVALUATION MATRIX: KEY PRODUCT PROVIDERS, 2024
- 15.5.1 STARS
- 15.5.2 EMERGING LEADERS
- 15.5.3 PERVASIVE PLAYERS
- 15.5.4 PARTICIPANTS
- 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
- 15.5.5.1 Company footprint
- 15.5.5.2 Region footprint
- 15.5.5.3 Product type footprint
- 15.5.5.4 Workflow footprint
- 15.5.5.5 Application footprint
- 15.6 COMPANY EVALUATION MATRIX: KEY SERVICE PROVIDERS, 2024
- 15.6.1 STARS
- 15.6.2 EMERGING LEADERS
- 15.6.3 PERVASIVE PLAYERS
- 15.6.4 PARTICIPANTS
- 15.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
- 15.6.5.1 Company footprint
- 15.6.5.2 Region footprint
- 15.6.5.3 Service footprint
- 15.6.5.4 Application footprint
- 15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 15.7.1 PROGRESSIVE COMPANIES
- 15.7.2 RESPONSIVE COMPANIES
- 15.7.3 DYNAMIC COMPANIES
- 15.7.4 STARTING BLOCKS
- 15.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
- 15.7.5.1 Detailed list of key startups/SMEs
- 15.7.5.2 Competitive benchmarking of key startups/SMEs
- 15.8 COMPANY VALUATION & FINANCIAL METRICS
- 15.8.1 FINANCIAL METRICS
- 15.8.2 COMPANY VALUATION
- 15.9 BRAND/PRODUCT COMPARISON
- 15.9.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
- 15.10 COMPETITIVE SCENARIO
- 15.10.1 PRODUCT & SERVICE LAUNCHES
- 15.10.2 DEALS
16 COMPANY PROFILES
- 16.1 INTRODUCTION
- 16.2 KEY PRODUCT PROVIDERS
- 16.2.1 BECTON, DICKINSON AND COMPANY (BD)
- 16.2.1.1 Business overview
- 16.2.1.2 Products offered
- 16.2.1.3 Recent developments
- 16.2.1.3.1 Product launches
- 16.2.1.3.2 Deals
- 16.2.1.4 MnM view
- 16.2.1.4.1 Key strengths
- 16.2.1.4.2 Strategic choices
- 16.2.1.4.3 Weaknesses & competitive threats
- 16.2.2 THERMO FISHER SCIENTIFIC INC.
- 16.2.2.1 Business overview
- 16.2.2.2 Products offered
- 16.2.2.3 Recent developments
- 16.2.2.3.1 Product launches
- 16.2.2.4 MnM view
- 16.2.2.4.1 Key strengths
- 16.2.2.4.2 Strategic choices
- 16.2.2.4.3 Weaknesses & competitive threats
- 16.2.3 DANAHER CORPORATION
- 16.2.3.1 Business overview
- 16.2.3.2 Products offered
- 16.2.3.3 Recent developments
- 16.2.3.3.1 Product launches
- 16.2.3.3.2 Deals
- 16.2.3.4 MnM view
- 16.2.3.4.1 Key strengths
- 16.2.3.4.2 Strategic choices
- 16.2.3.4.3 Weaknesses & competitive threats
- 16.2.4 10X GENOMICS
- 16.2.4.1 Business overview
- 16.2.4.2 Products offered
- 16.2.4.3 Recent developments
- 16.2.4.3.1 Product launches
- 16.2.4.3.2 Deals
- 16.2.4.4 MnM view
- 16.2.4.4.1 Key strengths
- 16.2.4.4.2 Strategic choices
- 16.2.4.4.3 Weaknesses & competitive threats
- 16.2.5 ILLUMINA, INC.
- 16.2.5.1 Business overview
- 16.2.5.2 Products offered
- 16.2.5.3 Recent developments
- 16.2.5.3.1 Product launches
- 16.2.5.3.2 Deals
- 16.2.5.4 MnM view
- 16.2.5.4.1 Key strengths
- 16.2.5.4.2 Strategic choices
- 16.2.5.4.3 Weaknesses & competitive threats
- 16.2.6 MERCK KGAA
- 16.2.6.1 Business overview
- 16.2.6.2 Products offered
- 16.2.7 QIAGEN N.V.
- 16.2.7.1 Business overview
- 16.2.7.2 Products offered
- 16.2.8 BIO-RAD LABORATORIES, INC.
- 16.2.8.1 Business overview
- 16.2.8.2 Products offered
- 16.2.8.3 Recent developments
- 16.2.8.3.1 Product launches
- 16.2.9 TECAN TRADING AG
- 16.2.9.1 Business overview
- 16.2.9.2 Products offered
- 16.2.9.3 Recent developments
- 16.2.9.3.1 Product launches
- 16.2.9.3.2 Deals
- 16.2.10 CYTEK BIOSCIENCES
- 16.2.10.1 Business overview
- 16.2.10.2 Products offered
- 16.2.10.3 Recent developments
- 16.2.10.3.1 Product launches
- 16.2.10.3.2 Deals
- 16.2.10.3.3 Expansions
- 16.2.11 TAKARA BIO INC.
- 16.2.11.1 Business overview
- 16.2.11.2 Products offered
- 16.2.11.3 Recent developments
- 16.2.11.3.1 Product launches
- 16.2.11.3.2 Deals
- 16.2.12 BIO-TECHNE
- 16.2.12.1 Business overview
- 16.2.12.2 Products offered
- 16.2.12.3 Recent developments
- 16.2.13 PACBIO
- 16.2.13.1 Business overview
- 16.2.13.2 Products offered
- 16.2.13.3 Recent developments
- 16.2.13.3.1 Product launches
- 16.3 KEY SERVICE PROVIDERS
- 16.3.1 AZENTA US INC.
- 16.3.1.1 Business overview
- 16.3.1.2 Services offered
- 16.3.2 NOVOGENE CO., LTD.
- 16.3.2.1 Business overview
- 16.3.2.2 Services Offered
- 16.3.2.3 Recent developments
- 16.3.2.3.1 Service launches
- 16.3.2.3.2 Expansions
- 16.3.3 IQVIA INC.
- 16.3.3.1 Business overview
- 16.3.3.2 Services offered
- 16.3.4 ALMAC GROUP
- 16.3.4.1 Business overview
- 16.3.4.2 Services offered
- 16.3.5 CEGAT GMBH
- 16.3.5.1 Business overview
- 16.3.5.2 Services offered
- 16.3.6 ACTIVE MOTIF
- 16.3.6.1 Business overview
- 16.3.6.2 Services offered
- 16.4 OTHER PRODUCT PROVIDERS
- 16.4.1 SINGLERON BIOTECHNOLOGIES
- 16.4.2 CELL MICROSYSTEMS
- 16.4.3 NANOCELLECT BIOMEDICAL
- 16.4.4 OXFORD NANOPORE TECHNOLOGIES PLC.
- 16.4.5 REVVITY
- 16.4.6 PARSE BIOSCIENCES
- 16.4.7 ULTIMA GENOMICS
- 16.4.8 MISSION BIO
- 16.5 OTHER SERVICE PROVIDERS
- 16.5.1 SINGLE CELL DISCOVERIES BV
- 16.5.2 ADMERA HEALTH
- 16.5.3 BGI
- 16.5.4 SIGNIOSBIO
- 16.5.5 MACROGEN CO., LTD.
- 16.5.6 LEXOGEN GMBH
- 16.5.7 DISCOVERY LIFE SCIENCES
- 16.5.8 CELLCARTA
- 16.5.9 SINGULOMICS CORPORATION
- 16.5.10 SEQMATIC LLC.
17 APPENDIX
- 17.1 DISCUSSION GUIDE
- 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 17.3 CUSTOMIZATION OPTIONS
- 17.4 RELATED REPORTS
- 17.5 AUTHOR DETAILS